- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Harmony Biosciences Holdings(HRMY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HRMY
11/13/2026: HRMY (1-star) is currently NOT-A-BUY. Pass it for now.
Harmony Biosciences Holdings is a commercial-stage biopharmaceutical stock known for solid profitability and strong operating margins driven by its flagship narcolepsy therapy, WAKIX. The company's primary investment appeal lies in its reliable cash generation, low valuation multiple, and ongoing pipeline expansion into rare neurological conditions. However, investors face single-product revenue concentration and clinical execution risks as it attempts to diversify beyond WAKIX. The stock suits value and growth investors seeking profitable healthcare exposure, provided they monitor ongoing patent defenses and clinical trial readouts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Harmony delivers attractive organic revenue growth and expanding earnings through its core commercial portfolio. |
| Momentum investor | Strong fit while signal remains positive | The stock attracts technical interest during positive clinical readouts and regulatory approval catalysts. |
| Value investor | Strong fit | The company trades at a notably low trailing P/E multiple relative to its profitability and growth rate. |
| Dividend investor | Weak fit | Harmony does not pay a dividend, focusing capital instead on reinvestment and pipeline expansion. |
| Low-risk investor | Mixed fit | While profitable and financially sound, single-product concentration and biotech clinical risks introduce volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotechnology equities often experience sharp price movements surrounding clinical trial data readouts and regulatory decisions. |
| Valuation risk | Low | The stock trades at a conservative earnings multiple, mitigating severe downside valuation compression. |
| Competition risk (CNS and narcolepsy therapeutics) | Medium | Intense market rivalry from established players like Jazz Pharmaceuticals requires ongoing commercial execution. |
| Business quality | Strong | The company boasts high operating margins, strong cash flows, and proven commercial capabilities. |
| Dividend income | Low / none | Income-focused investors will find no dividend support as earnings are reinvested. |
| Execution risk | Medium | Success relies heavily on clinical trial delivery for pipeline assets and defending market share for WAKIX. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.98B USD | Price to earnings Ratio 11.18 | 1Y Target Price 48.08 |
Price to earnings Ratio 11.18 | 1Y Target Price 48.08 | ||
Volume (30-day avg) 1.1M shares | Beta 0.98 | 52 Weeks Range 25.90 - 43.49 | Updated Date 11/15/2026 |
52 Weeks Range 25.90 - 43.49 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 3.02 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 45.5%
- Active BUY / eligible
- 20 / 44
- 30-Day BUY Count Change
- +13
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Moderately Choppy
The stock has experienced noticeable price swings while retaining some directional structure.
Analysis of Past Performance
Type Stock | Historic Profit -10.82% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| U.S. Commercial Pharmaceuticals | Net product sales generated primarily from the commercialization of WAKIX (pitolisant) in the United States market. | Virtually all of Harmony's revenue comes from selling its flagship narcolepsy drug to patients in the U.S. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When Before Market | Estimate 1 | Actual 0.81 |
Profitability
Profit Margin 18.05% | Operating Margin (TTM) 22.17% |
Management Effectiveness
Return on Assets (TTM) 10.21% | Return on Equity (TTM) 18.73% |
Valuation
Trailing PE 11.18 | Forward PE 8.38 | Enterprise Value 1.36B | Price to Sales(TTM) 2 |
Enterprise Value 1.36B | Price to Sales(TTM) 2 | ||
Enterprise Value to Revenue 1.37 | Enterprise Value to EBITDA 5.01 | Shares Outstanding 58.72M | Shares Floating 52.58M |
Shares Outstanding 58.72M | Shares Floating 52.58M | ||
Percent Insiders 2.11 | Percent Institutions 104.14 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

